Nadia Waheed

Chief Medical Officer at Applied Genetics Technologies Corporation

Nadia Waheed, MD, MPH has extensive experience as a retina specialist and in ocular imaging and clinical research. Most recently, she was Chief Medical Officer at Gyroscope Therapeutics, a retinal gene therapy company acquired by Novartis in 2022. She also has experience as Director of the Boston Image Reading Center and Professor in Ophthalmology and Consultant at the New England Eye Center, Tufts University School of Medicine.

Dr. Waheed received her medical degree from the Aga Khan University Medical School, Pakistan, and a Master in Public Health from the Harvard School of Public Health. She trained in Ophthalmology at the Harvard Medical School/Mass Eye and Ear Infirmary Program in Ophthalmology and completed a fellowship in retina at the Harvard Medical School/Mass Eye and Ear Infirmary. She then joined the Cleveland Clinic Cole Eye Institute as faculty and later established the Retina Unit at the Shifa Hospital, following which she joined the New England Eye Center.

Dr. Waheed has authored over 100 papers in peer-reviewed publications, has co-authored and edited three books in Ophthalmology, and has participated as a principal investigator or co-investigator in multiple clinical trials. She has been recognized by both the American Academy of Ophthalmology and the Macula Society with an Achievement Award.

Timeline

  • Chief Medical Officer

    Current role